Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | Chief Administrative Officer | June 01, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date June 01, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,840 |
Reported balance
After 2023-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-01 · Sale · Disposed 2,500 · Balance 106,840 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023. F2: Includes 926 shares of common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.
F2: Includes 926 shares of common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2023 Filed Jun 2, 2023 16:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,500 | $25.67 | $64,175.00 |
DisclosureSEC source: 0001209191-23-033551 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,840 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023. F2 · balance_after: Includes 926 shares of common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,795 | $25.97 | $46,621.54 |
DisclosureSEC source: 0001209191-23-012994 · doc4.xml · nonDerivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,414 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001209191-23-012994 · doc4.xml · derivative · entry 3 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2033-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012994 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,209 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,981 | $25.29 | $50,095.53 |
DisclosureSEC source: 0001209191-23-011385 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,209 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. F2 · balance_after: Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-012953 · doc4.xml · derivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012953 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,658 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,942 | $31.93 | $62,010.39 |
DisclosureSEC source: 0001209191-22-011750 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,658 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · derivative · entry 3 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,441 Underlying: Common Stock · 10,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · nonDerivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,000 | $12.76 | $127,600.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 600 shares of common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-21-053237 · doc4.xml · derivative · entry 3 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,441 Underlying: Common Stock · 10,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001209191-21-053237 · doc4.xml · nonDerivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 22:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,000 | $12.76 | $127,600.00 |
DisclosureSEC source: 0001209191-21-053237 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-21-043698 · doc4.xml · derivative · entry 3 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,441 Underlying: Common Stock · 3 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3 | $50.00 | $150.00 |
DisclosureSEC source: 0001209191-21-043698 · doc4.xml · nonDerivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3 | $12.76 | $38.28 |
DisclosureSEC source: 0001209191-21-043698 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $67.38 | $0.00 |
DisclosureSEC source: 0001209191-21-011917 · doc4.xml · derivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011917 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:45 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $47.06 | $0.00 |
DisclosureSEC source: 0001209191-20-044534 · doc4.xml · derivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-07-30 F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on July 30, 2021, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.